Facebook
Twitter
LinkedIn
Google+
ForwardAmerican Thyroid Association Satellite Symposium: The Spectrum of Thyroid Cancer, From Surveillance to Systemic Therapy - 2018 Enduring Activity
American Thyroid Association Satellite Symposium: The Spectrum of Thyroid Cancer, From Surveillance to Systemic Therapy - 2018 Enduring Activity
Target Audience
This continuing medical education activity should be of substantial interest to the community of endocrinologists, internists, surgeons, basic scientists, nuclear medicine scientists, pathologists, trainees, nurses, physician assistants, other health care professionals and the general public who wish to broaden and update their knowledge on hypothyroidism.
Learning Objectives
Upon completion of this educational activity, learners will be able to:
- Understand how the therapy of hypothyroidism has evolved since the first use of thyroid gland preparations
- Describe how TSH references intervals may vary for different populations and understand the impact of TSH values on outcomes, morbidity, and mortality
- List the factors other than serum TSH values, such as T3 levels and polymorphisms in TH transporters and deiodinases, that may potentially provide information about the thyroid status of patients
- Describe the potential benefits and risks of combination therapy, and weigh these factors in order to determine whether combination therapy should be offered to patients with hypothyroidism
- Review areas with significant knowledge gaps, such as whether measuring additional thyroid analytes beyond TSH and FT4 is helpful, and whether diet/dietary supplements impact thyroid function
- Describe how patient-centered outcomes might be incorporated into the management of patients with hypothyroidism
- Appreciate the patient perspective during the treatment of hypothyroidism
Additional Information
DISCLOSURE POLICY
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.
The ATA Guidelines Satellite Symposium faculty reported relevant financial relationship(s):
James V. Hennessey, MD: Consultant, AbbVie Inc., Allergen
Jacqueline Jonklaas, MD: Editorial board, JCEM, Thyroid
The ATA Guidelines Satellite Symposium faculty reported no relevant financial relationship(s) during the content development process for this activity: Antonio C. Bianco, MD, PhD; M. Regina Castro, MD; Anne R. Cappola, MD; Colin Mark Dayan MBBS PhD; Kimberly Dorris; Alan P. Farwell, MD; Judy O'Reilly; Douglas S Ross MD; Anna M. Sawka, MD, Peter N. Taylor, BSc, MBChB, MSc
The ATA Guidelines Satellite Symposium Program Committee member reported no relevant financial relationship (s): Peter Kopp, MD
The following Endocrine Society Special Programs Committee member who reviewed content for this activity reported financial relationships:
Giuseppe Barbesino, MD: Spouse, employee of Genzyme
The following SPC Committee members reported financial relationships:
Zahid Ahmad, MD: Research Support, Regeneron, FH Foundation; Consultant, Regeneron; Speaker, Amgen, Genzyme, Sanofi
Andrew Ahmann, MD: Research Support, DexCom, Lexicon, Medtronic, Novo Nordisk; Consultant, Dexco, Novo Nordisk, Trividia Health
John Carmichael, MD: Research Support, Novo Nordisk, Chiasma, Novartis, Pfizer, Strongbridge Biopharma; Speaker, Novartis; Advisory Board, Pfizer, Chiasma, Ionis Pharmaceuticals
Natalie Cusano, MD: Research Support, Shire; Speaker, Shire
Joan Han, MD: Research Support, Rhythm Pharmaceutical
Alan Kelly, MD: Speaker, Eli Lilly
E Michael Lewiecki, MD: Consultant, Amgen, Merck, Eli Lilly, Radius Health, Shire, Abbvie and Alexion; Speaker, Alexion, Shire; Research Grant Support, Amgen, Eli Lilly, Merck
Lisa Nachtigall, MD: Consultant, Ipsen, Novartis, Corcept; Grant Support/Investigator, Chiasma
Neda Rasouli, MD: Research Support, Novo Nordisk, Calibra, INTARCIA Therapeutics, GlaxoSmithKline, Bristol Meyer Squibb, AstraZeneca /Amylin, Ionis Pharmaceuticals, Boehringer Ingelheim
The Endocrine Society has reviewed these relationships to determine which are relevant to the content of this activity and resolved any identified conflicts of interest for these individuals.
The following SPC members reported no relevant financial relationships: Connie Newman, MD, Amy Rothberg, MD
The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Endocrine Society has achieved Accreditation with Commendation.
The Endocrine Society designates this live activity for a maximum of 4.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Available Credit
- 4.50 AMA PRA Category 1 Credits™
- 4.50 CME Certificate of Participation
- 4.50 RCP MOC